Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure. We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. METHODS: Patients were randomly assigned to eplerenone (25 mg per day initially, titrated to a maximum of 50 mg per day; 3319 patients) or placebo (3313 patients) [correction] in addition to optimal medical therapy. The study continued until 1012 deaths occurred. The primary end points were death from any cause and death from cardiovascular causes or hospitalization for heart failure, acute myocardial infarction, stroke, or ventricular arrhythmia. RESULTS: During a mean follow-up of 16 months, there were 478 deaths in the eplerenone group and 554 deaths in the placebo group (relative risk, 0.85; 95 percent confidence interval, 0.75 to 0.96; P=0.008). Of these deaths, 407 in the eplerenone group and 483 in the placebo group were attributed to cardiovascular causes (relative risk, 0.83; 95 percent confidence interval, 0.72 to 0.94; P=0.005). The rate of the other primary end point, death from cardiovascular causes or hospitalization for cardiovascular events, was reduced by eplerenone (relative risk, 0.87; 95 percent confidence interval, 0.79 to 0.95; P=0.002), as was the secondary end point of death from any cause or any hospitalization (relative risk, 0.92; 95 percent confidence interval, 0.86 to 0.98; P=0.02). There was also a reduction in the rate of sudden death from cardiac causes (relative risk, 0.79; 95 percent confidence interval, 0.64 to 0.97; P=0.03). The rate of serious hyperkalemia was 5.5 percent in the eplerenone group and 3.9 percent in the placebo group (P=0.002), whereas the rate of hypokalemia was 8.4 percent in the eplerenone group and 13.1 percent in the placebo group (P<0.001). CONCLUSIONS: The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Randomized controlled trial data regarding in-hospital initiation of MRA therapy among patients with HFrEF is limited to the EPHESUS trial.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [38]
In the citing paper
“Mineralocorticoid receptor antagonists (spironolactone, eplerenone) can also be effective antihypertensive agents (particularly for those with borderline or low potassium levels)89 and are important for morbidity and mortality reduction in patients with left ventricular dysfunction.90,91”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [90]
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Self-citationDickstein, K., & Kjekshus, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09895-1 · Cited by 1,203
Calculating the number needed to treat for trials where the outcome is time to an event
Altman, D. G., & Andersen, P. K. (1999) · BMJ · doi:10.1136/bmj.319.7223.1492 · Cited by 710
Aldosterone induces a vascular inflammatory phenotype in the rat heart
Rocha, R., Rudolph, A. E., Frierdich, G. E., Nachowiak, D. A., Kekec, B. K., Blomme, E. A. G., McMahon, E. G., & Delyani, J. A. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01096.2001 · Cited by 655
Aldosterone-Induced Inflammation in the Rat Heart
Sun, Y., Zhang, J., Lu, L., Chen, S. S., Quinn, M. T., & Weber, K. T. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64454-9 · Cited by 567
Farquharson, C. A. J., & Struthers, A. D. (2000) · Circulation · doi:10.1161/01.cir.101.6.594 · Cited by 532
Pitt, B., Williams, G., Remme, W., Martinez, F., Lopez-Sendon, J., Zannad, F., Neaton, J., Roniker, B., Hurley, S., Burns, D., et al. (2001) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1011119003788 · Cited by 364
Self-citation
Research works printed but not linked: 3
- Rodriguez JA, 1997, Rev Med Chile, 125, 643
- Schaefer A, 2002, Eur Heart J, 23, 401
- de Gasparo M, 1987, J Pharmacol Exp Ther, 240, 650
Cited by
Items 501–600 of 1,018
Bansal, S., Lindenfeld, J. M., & Schrier, R. W. (2009) · Circulation Heart Failure · doi:10.1161/circheartfailure.108.821199 · Cited by 128
Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure
Aronow, W. S. (2006) · Cardiology in Review · doi:10.1097/01.crd.0000175289.87583.e5 · Cited by 138
Cortisol metabolism in hypertension
Hammer, F., & Stewart, P. M. (2006) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2006.07.001 · Cited by 143
Funder, J. W. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2004.12.010 · Cited by 137
Acute Left Ventricular Remodeling Following Myocardial Infarction
Chan, W., Duffy, S. J., White, D. A., Gao, X., Du, X., Ellims, A., Dart, A. M., & Taylor, A. J. (2012) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2012.03.015 · Cited by 125
HAYASHI, H., KOBARA, M., ABE, M., TANAKA, N., GOUDA, E., TOBA, H., YAMADA, H., TATSUMI, T., NAKATA, T., & MATSUBARA, H. (2008) · Hypertension Research · doi:10.1291/hypres.31.363 · Cited by 117
Damman, K., Tang, W. H. W., Felker, G. M., Lassus, J., Zannad, F., Krum, H., & McMurray, J. J. V. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.031 · Cited by 122
Self-citationYamaji, M., Tsutamoto, T., Kawahara, C., Nishiyama, K., Yamamoto, T., Fujii, M., & Horie, M. (2009) · Circulation: Heart Failure · doi:10.1161/circheartfailure.109.868513 · Cited by 119
The past, present and future of renin–angiotensin aldosterone system inhibition
Mentz, R. J., Bakris, G. L., Waeber, B., McMurray, J. J. V., Gheorghiade, M., Ruilope, L. M., Maggioni, A. P., Swedberg, K., Piña, I. L., Fiuzat, M., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.10.007 · Cited by 118
Self-citationKosmala, W., Rojek, A., Przewłocka‐Kosmala, M., Wright, L. M., Mysiak, A., & Marwick, T. H. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.07.763 · Cited by 125
Mechanisms of Hypertension: The Expanding Role of Aldosterone
Freel, E. M., & Connell, J. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000132473.50966.14 · Cited by 144
The mineralocorticoid receptor and its coregulators
Yang, J., & Young, M. J. (2009) · Journal of Molecular Endocrinology · doi:10.1677/jme-09-0031 · Cited by 107
Svensson, M., Gustafsson, F., Galatius, S., Hildebrandt, P. R., & Atar, D. (2004) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2003.10.012 · Cited by 120
Lastra, G., Whaley-Connell, A., Manrique, C., Habibi, J., Gutweiler, A. A., Appesh, L., Hayden, M. R., Wei, Y., Ferrario, C., & Sowers, J. R. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00258.2007 · Cited by 119
White, W. B., Hanes, V., Chauhan, V., & Pitt, B. (2006) · Hypertension · doi:10.1161/01.hyp.0000232179.60442.84 · Cited by 119
Self-citationNicholl, D. D. M., Hanly, P. J., Poulin, M. J., Handley, G. B., Hemmelgarn, B. R., Sola, D. Y., & Ahmed, S. B. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201403-0526oc · Cited by 119
Primary aldosteronism: an update on screening, diagnosis and treatment
Rossi, G. P., Pessina, A. C., & Heagerty, A. M. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282f4b3e6 · Cited by 120
McGraw, A. P., Bagley, J., Chen, W., Galayda, C., Nickerson, H., Armani, A., Caprio, M., Carmeliet, P., & Jaffe, I. Z. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.112.000018 · Cited by 118
Guidelines for the management of acute coronary syndromes 2006
(2006) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2006.tb00304.x · Cited by 140
GUSTAFSSON, F., & ARNOLD, J. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.06.023 · Cited by 115
Lee, H., Lee, D.-Y., Cho, H., Kim, S.-Y., Iwasaki, Y., & Kim, I. K. (2013) · Circulation Research · doi:10.1161/circresaha.113.301071 · Cited by 121
New Therapeutic Targets in Cardiology: Arrhythmias and Ca2+/Calmodulin-Dependent Kinase II (CaMKII)
Rokita, A. G., & Anderson, M. E. (2012) · Circulation · doi:10.1161/circulationaha.112.124990 · Cited by 108
The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure
Pugliese, N. R., Masi, S., & Taddei, S. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09855-5 · Cited by 120
The Ubiquitous Mineralocorticoid Receptor: Clinical Implications
Hawkins, U. A., Gomez-Sanchez, E. P., Gomez-Sanchez, C. M., & Gomez-Sanchez, C. E. (2012) · Current Hypertension Reports · doi:10.1007/s11906-012-0297-0 · Cited by 112
Boccanelli, A., Mureddu, G. F., Cacciatore, G., Clemenza, F., Lenarda, A. D., Gavazzi, A., Porcu, M., Latini, R., Lucci, D., Maggioni, A. P., et al. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfn015 · Cited by 123
Braunschweig, F., Boriani, G., Bauer, A., Hatala, R., Herrmann-Lingen, C., Kautzner, J., Pedersen, S. S., Pehrson, S., Ricci, R., & Schalij, M. J. (2010) · Europace · doi:10.1093/europace/euq316 · Cited by 113
Hasui, T., Matsunaga, N., Ora, T., Ohyabu, N., Nishigaki, N., Imura, Y., Igata, Y., Matsui, H., Motoyaji, T., Tanaka, T., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2011645 · Cited by 122
Management of Heart Failure Patient with CKD
Banerjee, D., Rosano, G., & Herzog, C. A. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14180920 · Cited by 139
Cardiovascular and Renal Damage in Primary Aldosteronism: Outcomes After Treatment
Sechi, L. A., Colussi, G., Fabio, A. D., & Catena, C. (2010) · American Journal of Hypertension · doi:10.1038/ajh.2010.169 · Cited by 122
Heart failure burden and therapy
Zannad, F., Agrinier, N., & Alla, F. (2009) · Europace · doi:10.1093/europace/eup304 · Cited by 111
Self-citationAssmus, B., Leistner, D. M., Schächinger, V., Erbs, S., Elsässer, A., Haberbosch, W., Hambrecht, R., Sedding, D., Yu, J., Corti, R., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu062 · Cited by 116
Epidemiology of Chronic Kidney Disease in Heart Failure
Ahmed, A., & Campbell, R. C. (2008) · Heart Failure Clinics · doi:10.1016/j.hfc.2008.03.008 · Cited by 132
Effects of eplerenone versus losartan in patients with low-renin hypertension
Weinberger, M. H., White, W. B., Ruilope, L. M., MacDonald, T. M., Davidson, R. C., Roniker, B., Patrick, J. L., & Krause, S. L. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.12.005 · Cited by 115
Self-citationFonarow, G. C., Yancy, C. W., Albert, N. M., Curtis, A. B., Stough, W. G., Gheorghiade, M., Heywood, J. T., Mehra, M. R., O’Connor, C. M., REYNOLDS, D. W., et al. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.03.030 · Cited by 119
MANAGEMENT OF END STAGE HEART FAILURE
Friedrich, E. B., & Böhm, M. (2007) · Heart · doi:10.1136/hrt.2006.098814 · Cited by 130
I Diretriz Latino-Americana para avaliação e conduta na insuficiência cardíaca descompensada
Bocchi, E. A., Vilas‐Boas, F., Perrone, S. V., Caamaño, A. G., Clausell, N., Moreira, M. D. C. V., Thierer, J. M., Grancelli, H., Junior, C. V. S., de Albuquerque, D. C., et al. (2005) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2005002200001 · Cited by 142
Jering, K., Claggett, B. L., Pfeffer, M. A., Granger, C. B., Køber, L., Lewis, E. F., Maggioni, A. P., Mann, D. L., McMurray, J. J. V., Rouleau, J. L., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2191 · Cited by 123
Effect of Aldosterone and Mineralocorticoid Receptor Blockade on Vascular Inflammation
Joffe, H. V., & Adler, G. K. (2005) · Heart Failure Reviews · doi:10.1007/s10741-005-2346-0 · Cited by 114
Macchia, A., Levantesi, G., Franzosi, M. G., Geraci, E., Maggioni, A. P., Marfisi, R., Nicolosi, G. L., Schweiger, C., Tavazzi, L., Tognoni, G., et al. (2005) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.04.008 · Cited by 113
Savarese, G., Xu, H., Trevisan, M., Dahlström, U., Rossignol, P., Pitt, B., Lund, L. H., & Carrero, J. J. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2018.10.003 · Cited by 113
Self-citationCost-Effectiveness of Cardiac Resynchronization Therapy in Patients with Symptomatic Heart Failure
Nichol, G., Kaul, P., Huszti, E., & Bridges, J. F. P. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-5-200409070-00102 · Cited by 114
de Diagnóstico, G. D. T., & de Cardiología, T. D. L. I. C. C. D. L. S. E. (2005) · Revista Española de Cardiología · doi:10.1157/13078554 · Cited by 125
Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension
Colussi, G., Catena, C., & Sechi, L. A. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283599b6a · Cited by 108
Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis
Tesch, G. H., & Young, M. J. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00313 · Cited by 119
The Role of the Mineralocorticoid Receptor in Inflammation: Focus on Kidney and Vasculature
Belden, Z., Deiuliis, J. A., Dobre, M. A., & Rajagopalan, S. (2017) · American Journal of Nephrology · doi:10.1159/000480652 · Cited by 119
The Cardiorenal Syndrome in Heart Failure
Damman, K., Voors, A. A., Navis, G. J., van Veldhuisen, D. J., & Hillege, H. L. (2011) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2011.01.003 · Cited by 117
Aldosterone Blockade: An Emerging Strategy for Abrogating Progressive Renal Disease
Epstein, M. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.03.038 · Cited by 119
Aldosterone as a Cardiovascular Risk Factor
Yoo, S. J. (2007) · Journal of Korean Endocrine Society · doi:10.3803/jkes.2007.22.1.8 · Cited by 112
Pérez‐Rojas, J. M., Blanco, J. A., Cruz, C., Trujillo, J., Vaidya, V. S., Uribe, N., Bonventre, J. V., Gamba, G., & Bobadilla, N. A. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00147.2006 · Cited by 121
Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis
Neefs, J., van den Berg, N. W. E., Limpens, J., Berger, W. R., Boekholdt, S. M., Sanders, P., & de Groot, J. R. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.12.029 · Cited by 111
Blood pressure and amiloride-sensitive sodium channels in vascular and renal cells
Warnock, D. G., Kusche-Vihrog, K., Tarjus, A., Sheng, S., Oberleithner, H., Kleyman, T. R., & Jaisser, F. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.275 · Cited by 111
Aldosterone Stimulates Epidermal Growth Factor Receptor Expression
Krug, A. W., Großmann, C., Schuster, C., Freudinger, R., Mildenberger, S., Govindan, M. V., & Gekle, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308134200 · Cited by 122
Kobayashi, N., Yoshida, K., Nakano, S., Ohno, T., Honda, T., Tsubokou, Y., & Matsuoka, H. (2006) · Hypertension · doi:10.1161/01.hyp.0000203148.42892.7a · Cited by 110
Lax, A., Sánchez‐Más, J., Lopez, M., Palacio, M. J. F., Caballero, L., Garrido, I. P., Pastor‐Pérez, F. J., Januzzi, J. L., & Pascual-Figal, D. A. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2014.07.015 · Cited by 119
30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Nongenomic effects via the mineralocorticoid receptor
Ruhs, S., Nolze, A., Hübschmann, R., & Großmann, C. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0659 · Cited by 123
Gómez, A. M., Rueda, A., Sainte-Marie, Y., Pereira, L., Zissimopoulos, S., Zhu, X., Schaub, R., Perrier, E., Perrier, R., Latouche, C., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.805804 · Cited by 103
The 45-year story of the development of an anti-aldosterone more specific than spironolactone
Ménard, J. (2003) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.10.008 · Cited by 111
Prediction and prevention of sudden cardiac death in heart failure
Lane, R., Cowie, M., & CHOW, A. W. C. (2005) · Heart · doi:10.1136/hrt.2003.025254 · Cited by 119
The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma
Rothhammer-Hampl, T., Hahne, J. C., Florin, A., Poser, I., Soncin, F., Wernert, N., & Bosserhoff, A. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3337-8 · Cited by 117
Unger, T., Paulis, L., & Sica, D. A. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr253 · Cited by 119
Mineralocorticoid Receptor Antagonism Treats Obesity-Associated Cardiac Diastolic Dysfunction
Bender, S. B., DeMarco, V. G., Padilla, J., Jenkins, N. T., Habibi, J., Garro, M., Pulakat, L., Aroor, A. R., Jaffe, I. Z., & Sowers, J. R. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04912 · Cited by 108
Charytan, D. M., Himmelfarb, J., Ikizler, T. A., Raj, D. S., Hsu, J. Y., Landis, J. R., Anderson, A. H., Hung, A. M., Mehrotra, R., Sharma, S., et al. (2018) · Kidney International · doi:10.1016/j.kint.2018.08.034 · Cited by 112
Remodelação ventricular pós-infarto do miocárdio: conceitos e implicações clínicas
Zornoff, L. A. M., de Paiva, S. A. R., Duarte, D. R., & Spadaro, J. (2009) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2009000200013 · Cited by 147
Voets, M., Antes, I., Scherer, C., Müller‐Vieira, U., Biemel, K. M., Marchais‐Oberwinkler, S., & Hartmann, R. W. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060055x · Cited by 117
Aldosterone: A forgotten mediator of the relationship between psychological stress and heart disease
Kubzansky, L. D., & Adler, G. K. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.07.005 · Cited by 103
Mineralocorticoid receptors in immune cells: Emerging role in cardiovascular disease
Bene, N. C., Alcaide, P., Wortis, H. H., & Jaffe, I. Z. (2014) · Steroids · doi:10.1016/j.steroids.2014.04.005 · Cited by 112
Therapeutic strategies to slow chronic kidney disease progression
Wühl, E., & Schaefer, F. S. (2008) · Pediatric Nephrology · doi:10.1007/s00467-008-0789-y · Cited by 122
Endemann, D., Touyz, R. M., Iglarz, M., Savoia, C., & Schiffrin, E. L. (2004) · Hypertension · doi:10.1161/01.hyp.0000128031.31572.a3 · Cited by 109
Aldosterone Receptor Antagonists: Effective but Often Forgotten
Maron, B. A., & Leopold, J. A. (2010) · Circulation · doi:10.1161/circulationaha.109.895235 · Cited by 103
Estrogen Receptor Inhibits Mineralocorticoid Receptor Transcriptional Regulatory Function
Mueller, K. B., Lu, Q. R., Mohammad, N. N., Luu, V., McCurley, A., Williams, G. H., Adler, G. K., Karas, R. H., & Jaffe, I. Z. (2014) · Endocrinology · doi:10.1210/en.2014-1270 · Cited by 108
2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary
Heidenreich, P. A., Bozkurt, B., Aguilar, D. A., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A. M., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.02.009 · Cited by 118
Masoudi, F. A., Gross, C. P., Wang, Y., Rathore, S. S., Havranek, E. P., Foody, J. M., & Krumholz, H. M. (2005) · Circulation · doi:10.1161/circulationaha.104.527549 · Cited by 110
Heart Failure in African Americans
Yancy, C. W. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.028 · Cited by 112
Extrarenal effects of aldosterone
Cat, A. N. D., & Jaisser, F. (2012) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32834fb25b · Cited by 115
Minireview: Aldosterone and Mineralocorticoid Receptors: Past, Present, and Future
Funder, J. W. (2010) · Endocrinology · doi:10.1210/en.2010-0465 · Cited by 100
DuPont, J. J., & Jaffe, I. Z. (2017) · Journal of Endocrinology · doi:10.1530/joe-17-0009 · Cited by 110
Ohtani, T., Ohta, M., Yamamoto, K., Mano, T., Sakata, Y., Nishio, M., Takeda, Y., Yoshida, J., Miwa, T., Okamoto, M., et al. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00402.2006 · Cited by 104
White, W. B., Pitt, B., Preston, R. A., & Hanes, V. (2005) · Circulation · doi:10.1161/circulationaha.104.501502 · Cited by 108
Self-citationEfficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease
Beldhuis, I. E., Myhre, P. L., Claggett, B., Damman, K., Fang, J. C., Lewis, E. F., O’Meara, E., Pitt, B., Shah, S. J., Voors, A. A., et al. (2019) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.10.017 · Cited by 103
Self-citationPitt, B. (2003) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.10.009 · Cited by 117
Self-citationManagement of cardiovascular disease in patients with kidney disease
Kahn, M. R., Robbins, M. J., Kim, M. C., & Fuster, V. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.15 · Cited by 115
Tarjus, A., Martínez‐Martínez, E., Amador, C. A., Latouche, C., Moghrabi, S. E., Berger, T., Mak, T. W., Fay, R., Farman, N., Rossignol, P., et al. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.05431 · Cited by 105
Self-citationRole of Mineralocorticoid Receptor Antagonists in Cardiovascular Disease
Ferrario, C. M., & Schiffrin, E. L. (2014) · Circulation Research · doi:10.1161/circresaha.116.302706 · Cited by 105
Hernández-Tejedor, A., Peñuelas, Ó., Sirgo, G., Llompart-Pou, J. A., Herrejon, E. P., Estella, Á., Cabanes, M. P. F., Alcalá-Llorente, M. A., Galleymore, P. R., Azuara, B. O., et al. (2017) · Medicina Intensiva · doi:10.1016/j.medin.2017.03.004 · Cited by 114
Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
Agarwal, R., Ruilope, L. M., Ruiz‐Hurtado, G., Haller, H. G., Schmieder, R. E., Anker, S. D., Filippatos, G. S., Pitt, B., Rossing, P. R., Lambelet, M., et al. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003330 · Cited by 117
Self-citationStudy of Aldosterone Synthase Inhibition as an Add‐On Therapy in Resistant Hypertension
Karns, A. D., Bral, J. M., Hartman, D., Peppard, T., & Schumacher, C. (2013) · The Journal of Clinical Hypertension · doi:10.1111/jch.12051 · Cited by 104
Aldosterone induces trained immunity: the role of fatty acid synthesis
van der Heijden, C. D. C. C., Keating, S. T., Groh, L. A., Joosten, L. A. B., Netea, M. G., & Riksen, N. P. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz137 · Cited by 112
Aldosterone synthase inhibition in humans
Azizi, M., Amar, L., & Ménard, J. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs388 · Cited by 112
Alexandrou, M.-E., Papagianni, A., Tsapas, A., Loutradis, C., Boutou, A., Piperidou, A., Papadopoulou, D., Ruilope, L., Bakris, G., & Sarafidis, P. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002187 · Cited by 101
Gap Junction Remodeling and Spironolactone-Dependent Reverse Remodeling in the Hypertrophied Heart
Qu, J., Volpicelli, F., García, L. I., Sandeep, N., Zhang, J., Márquez‐Rosado, L., Lampe, P. D., & Fishman, G. I. (2008) · Circulation Research · doi:10.1161/circresaha.108.184044 · Cited by 103
Krug, A. W., & Ehrhart‐Bornstein, M. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.109439 · Cited by 105
Krogager, M. L., Eggers‐Kaas, L., Aasbjerg, K., Mortensen, R. N., Køber, L., Gislason, G., Torp-Pedersen, C. T., & Søgaard, P. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv026 · Cited by 104
I Diretriz Latino-Americana para o Diagnóstico e Tratamento da Cardiopatia Chagásica
Castro, I., de Andrade, J. P., de Paola, Â. A. V., Vilas‐Boas, F., de Oliveira, G. M. M., Marin‐Neto, J. A., Chagas, A. C. P., Rocha, E. A. V., de Oliveira, G. M. M., Zimerman, L. I., et al. (2011) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2011001600001 · Cited by 106
Bellera, N., Barba, I., Rodríguez‐Sinovas, A., Ferret, E., Asin, M.-A., Gonzalez‐Alujas, M., Pérez‐Rodon, J., Esteves, M., Fonseca, C., Torán, N., et al. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.000946 · Cited by 104
Accelerated and personalized therapy for heart failure with reduced ejection fraction
Shen, L., Jhund, P. S., Docherty, K. F., Vaduganathan, M., Petrie, M. C., Desai, A. S., Køber, L., Schou, M., Packer, M., Solomon, S. D., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac210 · Cited by 110
Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease
Hadoke, P. W. F., Iqbal, J., & Walker, B. R. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00047.x · Cited by 99
Gross, E. E., Rothstein, M., Dombek, S., & Juknis, H. I. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.03.005 · Cited by 102
Cleland, J. G. F., Torabi, A., & Khan, N. K. (2005) · Heart · doi:10.1136/hrt.2005.062026 · Cited by 118
White, H. D., Aylward, P. E., Huang, Z., Dalby, A. J., Weaver, W. D., Barvik, S., Marin‐Neto, J. A., Murín, J., Nordlander, R., van Gilst, W. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.551143 · Cited by 113
Self-citationAßmus, B., Tonn, T., Seeger, F. H., Yoon, C., Leistner, D. M., Klotsche, J., Schächinger, V., Seifried, E., Zeiher, A. M., & Dimmeler, S. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.059 · Cited by 107
Metadata
- Authors
- Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M.
- Affiliations
- University of Michigan (US)
- Cardiovascular Research Foundation (US)
- University of Minnesota (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-03
- Volume
- 348
- Issue
- 14
- Pages
- 1309-1321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152094259
- Cited by
- 4,941
- References
- 27
- Citations by year
- 2026: 120 · 2025: 148 · 2024: 136 · 2023: 150 · 2022: 155 · 2021: 156 · 2020: 164 · 2019: 147 · 2018: 187 · 2017: 188 · 2016: 177 · 2015: 224 · 2014: 239 · 2013: 270 · 2012: 281
- FWCI
- 180.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- eplerenone, mineralocorticoid receptor antagonists, left ventricular dysfunction, myocardial infarction, heart failure, cardiovascular mortality, sudden cardiac death, hyperkalemia, hypokalemia, hospitalization, ventricular arrhythmias, mortality reduction, secondary prevention
- MeSH terms
- Eplerenone, Aged, Mineralocorticoid Receptor Antagonists, Blood Pressure, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Myocardial Infarction, Potassium, Spironolactone, Survival Analysis, Death, Sudden, Cardiac, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.